舌下神经刺激对消费级睡眠技术指标及患者症状的影响
本病例系列纳入7例对舌下神经刺激器(HGNS)治疗有效的阻塞性睡眠呼吸暂停(OSA)患者,使用可穿戴消费级睡眠技术(CST)进行8周监测。参与者在HGNS开启状态下随机分为第4周或第5周关闭治疗,随后恢复治疗。结果显示,关闭HGNS期间OSA相关症状问卷评分显著恶化,而CST指标与症状评分存在相关性,提示CST可能有助于OSA患者的纵向睡眠追踪。
要点
- 关闭HGNS治疗1周可导致OSA相关睡眠症状问卷评分显著恶化。
- 可穿戴CST测量的睡眠指标与症状问卷评分存在相关性。
- CST指标在HGNS治疗各阶段无统计学显著变化。
核心结论
- 为期1周的HGNS治疗撤除会影响OSA相关睡眠症状。
- 可穿戴CST测量的睡眠相关指标与症状评分相关,提示CST在OSA患者纵向睡眠追踪中具有潜在价值。
研究设计与样本
- 本研究为病例系列,纳入7例对HGNS治疗有效的患者,使用可穿戴CST进行为期8周的研究。
- 参与者先处于HGNS开启状态,随机分配至第4周或第5周关闭HGNS治疗(HGNS关闭期),随后恢复治疗(HGNS恢复期)。
- 参与者每周完成经验证的症状问卷,评估嗜睡、失眠症状、功能状态和整体睡眠健康(SATED)。
主要发现
- 7名参与者共提供304晚的CST数据,总睡眠时间(TST)、入睡后觉醒时间和睡眠效率(SE)在研究各阶段无统计学显著变化。
- 在HGNS关闭期间,问卷评分显示OSA相关症状评分显著恶化。
- 2名参与者在HGNS关闭期间的心率变异性(HRV)较HGNS治疗活跃期显著升高,分别升高3.3 ms和6.3 ms。
- SATED评分与TST相关(r = 0.434,p < 0.0001),与HRV相关(r = -0.486,p < 0.0001),与SE相关(r = 0.320,p = 0.0014)。
- FOSQ-10评分与睡眠期间平均心率相关(r = -0.489,p < 0.001)。
局限性
- 证据等级为4级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Obstructive sleep apnea (OSA) is usually assessed at discrete and infrequent timepoints. Wearable consumer sleep technologies (CST) may allow for more granular and longitudinal assessments of OSA therapy responses and OSA-related symptoms. METHODS: In this case series, we enrolled hypoglossal nerve stimulator (HGNS) patients who had an effective treatment response for an 8-week study using a wearable CST. Participants started with "HGNS-on," were randomized to turn off HGNS therapy during either week 4 or 5 ("HGNS-off"), followed by a return to therapy, "HGNS-resume." Participants completed validated symptom questionnaires assessing sleepiness, insomnia symptoms, functional status, and overall sleep health (Satisfaction, Alertness, Timing, Efficiency, and Duration, SATED) each week. CST metrics and survey scores were compared between HGNS treatment phases. Associations between CST metrics and survey scores were assessed. RESULTS: Seven participants with a total of 304 nights of CST data showed no statistically significant changes in total sleep time (TST), wake time after sleep onset, or sleep efficiency (SE) across the study periods. During HGNS-off, survey scores indicated significantly worsened OSA-related symptom scores. Two participants had significantly higher heart rate variability (HRV) during HGNS-off (by 3.3 and 6.3 ms) when compared to HGNS active therapy periods. Amongst CST metrics, SATED scores correlated with TST (r = 0.434, p < 0.0001), HRV (r = -0.486, p < 0.0001), and SE (r = 0.320, = 0.0014). In addition, FOSQ-10 scores correlated with average HR during sleep (r = -0.489, p < 0.001). CONCLUSION: A 1-week HGNS therapy withdrawal period impacted OSA-related sleep symptoms. Sleep-related metrics measured by a wearable CST correlated with symptom scores indicating potential value in the use of CSTs for longitudinal sleep-tracking in OSA patients. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:3406-3411, 2024.
引用
- Cai Y, Zheng YJ, Cheng CM, et al. Impact of Hypoglossal Nerve Stimulation on Consumer Sleep Technology Metrics and Patient Symptoms. Laryngoscope. 2024. PMID: 38516821. doi:10.1002/lary.31398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。